GSI-136 is a γ-Secretase Inhibitor. GSI-136 was developed by Wyeth (now a subsidiary of Pfizer) for AD treatment and evaluated in phase I clinical trials to determine its safety and tolerability in healthy subjects. The evaluation of this drug has been extended to other diseases. However, no information about the outcomes of the trials is presently available. References:

纯度：≥98%

CAS：443989-01-3